Two tumoral CD19+ models, Nalm6-GFP-Nluc (B cell acute lymphoblastic leukemia [B-ALL] derived) and Namalwa-GFP-Nluc (Burkitt’s lymphoma derived) were incubated with both CAR-T cells and the different parameters analyzed as indicated in Figure 3A. Interestingly, AWARI CAR-T cells secreted lower levels of TNF-α and IFN-γ compared with ARI cells (Figure 3B) but maintain a similar anti-tumoral efficacy against Nalm6 and Namalwa (Figure 3C). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.